Discover an S1P Optimized to Target With Selectivity1

Graphic depicting that ZEPOSIA® blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood

ZEPOSIA blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.1

Graphic depicting that ZEPOSIA® blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood

ZEPOSIA blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.1

The mechanism by which ZEPOSIA exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.1

Graphic depicting the S1P receptor Graphic depicting the S1P receptor
  • T and B lymphocytes, other immune cells2
  • Astrocytes, neurons3
  • Vascular endothelial cells, cardiac myocytes4

Vascular endothelial, smooth muscle cells4,6

Cardiac myocytes5

  • T lymphocytes6
  • Megakarocytes7
  • Natural killer cells
  • Oligodendrocytes
  • Vascular endothelial cells6

Ozanimod is an S1P receptor modulator that binds with a high affinity to S1P receptors 1 and 5 and has little activity on other S1P receptors (S1P2, S1P3, and S1P4)1,8

Get your patients
started on ZEPOSIA
PATIENT
START FORM
Enroll your patients in ZEPOSIA 360 Support
and help them get started on treatment.
GETTING STARTED VIDEO
Helpful instructions to guide you through the process of getting your patients started on ZEPOSIA.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.